Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Regulatory News


Notice of half year results

Tue, 21st Nov 2017 09:51


RNS Number : 0771X
Abzena PLC
21 November 2017
 

Abzena plc

 

Notice of half year results

 

Cambridge, UK, 21 November 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its half year results for the six months to 30 September 2017 on Tuesday, 12 December 2017.

 

A presentation for analysts will be held at 09:30am on 12 December 2017 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.    

 

-Ends-

 

Enquiries:

 

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

 

+44 1223 903498

Numis (Nominated Adviser and Broker)

Clare Terlouw / James Black / Paul Gillam

 

+44 20 7260 1000

N+1 Singer (Joint Broker)

Aubrey Powell / Liz Yong

 

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Alex Shaw / Deborah Bell

 

+44 20 7457 2020

abzena@instinctif.com

 

 

About Abzena


Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

·      Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

·      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

·      Cell line development for the manufacture of recombinant proteins and antibodies;

·      Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

·      Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

·      Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

·      GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORMMMZMRMDGNZG


Related Shares:
Abzena (ABZA)



Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.